预约演示
更新于：2025-12-23
Ferrous Succinate
琥珀酸亚铁
更新于：2025-12-23
概要
基本信息
原研机构- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期- |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C4H6FeO4 |
InChIKeyVAMMNAAZSNNEDJ-UHFFFAOYSA-N |
CAS号10030-90-7 |
关联
34
项与 琥珀酸亚铁 相关的临床试验NCT05349630
Impact of Iron Supplementation on Right Ventricular Function and Exercise Performance in Hypoxia (A Sub-Study)
ChiCTR2300078484
A multi-center, randomized, double-blind, parallel-controlled clinical study on the effectiveness and safety of compound E Jiao Jiang in the treatment of anemia in the middle and late stages of pregnancy
CTRI/2023/07/055032
A Comparative Clinical Evaluation of Mandoor Bhasma and Ferrous Sulphate Tablets in Garbhini Pandu (Anaemia in Prergnancy) - NIL
100 项与 琥珀酸亚铁 相关的临床结果
登录后查看更多信息
100 项与 琥珀酸亚铁 相关的转化医学
登录后查看更多信息
100 项与 琥珀酸亚铁 相关的专利（医药）
登录后查看更多信息
94
项与 琥珀酸亚铁 相关的文献（医药）2025-02-01Stroke and Vascular Neurology
Efficacy and safety of Ferrous iron on the prevention of Vascular cOgnitive impaiRment among patients with cerebral Infarction/TIA (FAVORITE): rationale and design of a multicentre randomised trial
Article
作者: Xiong, Yunyun ; Hong, Zhen ; Wang, Yinkai ; Jia, Qian ; Yuan, Baoshi ; Zhou, Qi ; Lei, Peng ; Jia, Wei Li ; Yang, Yu ; Li, Zixiao ; Meng, Xia ; Wang, Yilong ; Zhang, Shuting ; Jing, Jing ; Lin, Jinxi ; Zhao, Xingquan ; Wang, Yongjun ; Sun, Li ; Wang, Anxin ; Pan, Yuesong
Background:
The incidence of vascular cognitive impairment (VCI) is high in patients suffering from ischaemic stroke or transient ischaemic attack (TIA) or with vascular risk factors. Effective prevention strategies for VCI remain limited. Anaemia or low haemoglobin was found as an independent risk factor for adverse outcomes after acute stroke. Anaemia or low haemoglobin was possibly associated with an increased risk of poststroke cognitive impairment. Whether supplement of ferrous iron to correct anaemia reduces the risk of VCI and improves adverse outcomes in patients with ischaemic cerebrovascular disease remains uncertain.
Aim:
We aim to introduce the design and rationale of the safety and efficacy of Ferrous iron on the prevention of Vascular cOgnitive impaiRment in patients with cerebral Infarction or TIA (FAVORITE) trial.
Design:
FAVORITE is a randomised, placebo-controlled, double-blind, multicentre trial that compares supplement of ferrous iron with placebo for recent minor stroke/TIA patients complicated with mild anaemia or iron deficiency: Ferrous succinate sustained-release tablet 0.2 g (corresponding to 70 mg of elemental iron) once daily after or during breakfast for 12 weeks or placebo with much the same colour, smell and size as ferrous iron once daily during or after breakfast for 12 weeks. All paticipants will be followed within the next year.
Study outcomes:
The primary effective outcome is the incidence of VCI at 3 months after randomisation and the primary safety outcome includes any gastrointestinal adverse event during 3 months.
Discussion:
The FAVORITE trial will clarify whether supplement of ferrous iron to correct low haemoglobin reduces the risk of VCI in patients with recent ischaemic stroke or TIA complicated with mild anaemia or iron deficiency compared with placebo.
Trial registration number:
NCT03891277
2025-01-01INTEGRATIVE CANCER THERAPIES
Effectiveness of Shuanghuang Yangxue Decoction for Treating Cancer-Related Anemia With Serum Iron Deficiency in Lung Cancer Patients: A Randomized Clinical Trial
Article
作者: Li, Quan-yao ; Yang, Wen-xiao ; Xu, Ling ; Yao, Jia-lin ; Li, Xi ; Liu, Hui ; Shi, Jun ; Yao, Li-qiu ; Lu, Ying ; Wang, Qin ; Qiu, Wen-chao ; Lin, Dan ; Mu, Hui ; Xue, Pei-pei ; Qian, Chen
Objective::
To evaluate the clinical efficacy and safety of Shuanghuang Yangxue Decoction in treating lung cancer patients with cancer-related anemia (CRA) accompanied by serum iron deficiency.
Method::
One hundred lung cancer patients with CRA and serum iron deficiency were included in this prospective randomized controlled study and randomly divided into control and treatment groups. The treatment group received Shuanghuang Yangxue Decoction plus ferrous succinate, while the control group received ferrous succinate alone. Related indicators were observed and recorded before and after treatment. Statistical analysis was performed using SPSS 26.0.
Results::
The effective correction rate of anemia in the treatment group was significantly higher than that in the control group (64 vs 34%,
P
< .01). Through stratified analysis of patients with moderate anemia, the effective correction rate in the treatment group was significantly higher than that in the control group (75 vs 45%,
P
< 0.01). After treatment, the treatment group showed statistically significant differences (
P
< .05) in peripheral blood routine parameters (hemoglobin, erythrocyte count, and hematocrit), anemia indicators (serum iron, ferritin, transferrin saturation, and erythropoietin [EPO]), immune function markers (cytotoxic T lymphocytes [Tc] and natural killer [NK] lymphocytes), and inflammatory factors (interleukin-1β [IL-1β], IL-6, tumor necrosis factor-α [TNF-α], and interferon-γ [IFN-γ]) compared to baseline values. Between-group comparisons showed that mean hemoglobin in the treatment group increased from 106.60 to 119.86 g/L, which was not significantly different from the control group increase from 110.00 to 116.18 g/L (
P
> .05). However, mean serum iron in the treatment group increased from 7.03 to 12.33 μmol/L, which was significantly higher than the control group increase from 7.33 to 9.45 μmol/L (
P
< .01). Throughout the study, no adverse reaction events occurred in either group.
Conclusion::
Shuanghuang Yangxue Decoction demonstrates superior efficacy compared to ferrous succinate alone in treating lung cancer CRA with serum iron deficiency. It effectively corrects anemia, increases serum iron levels, reduces inflammation, and is both safe and effective.
2024-11-05Critical reviews in food science and nutrition
Advances on novel iron saccharide-iron (III) complexes as nutritional supplements
Review
作者: Wassie, Teketay ; Feng, Yingying ; Wu, Yuying ; Wu, Xin
Iron deficiency is prevalent worldwide, and iron supplementation is a promising strategy to address iron needs of the body. However, traditional oral supplements such as ferrous sulfate, ferrous succinate, and ferrous gluconate are absorbed in the form of ferrous ions, leading to lipid peroxidation and side effects due to other reasons. In recent years, saccharide-iron (III) complexes (SICs) as novel iron supplements have aroused attention for the high iron absorption rate and no gastrointestinal irritation at oral doses. In addition, research on the biological activities of SICs revealed that they also exhibited good abilities in treating anemia, eliminating free radicals, and regulating the immune response. This review focused on the preparation, structural characterization, and bioactivities of these new iron supplements, as promising candidates for the prevention and treatment of iron deficiency.
100 项与 琥珀酸亚铁 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 缺铁性贫血 | 中国 | 1993-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 27 | Placebo for ferrous fumarate+Ferinject (Ferinject) | 積壓範艱餘構襯鏇艱糧(製簾範觸憲鬱築襯淵積) = 簾齋選膚廠網餘顧夢築 夢衊窪窪獵鏇餘憲網鹹 (壓範鏇壓壓淵繭選齋積, 糧鏇觸觸醖廠衊齋蓋繭 ~ 憲窪淵衊廠製選廠繭衊) 更多 | - | 2022-08-22 | ||
Placebo for ferinject+Ferrous fumarate (Ferrous Fumarate) | 積壓範艱餘構襯鏇艱糧(製簾範觸憲鬱築襯淵積) = 鏇網獵鹽夢窪膚觸襯衊 夢衊窪窪獵鏇餘憲網鹹 (壓範鏇壓壓淵繭選齋積, 淵積夢繭艱膚壓鏇鹹鬱 ~ 窪襯憲簾獵網築鹽選齋) 更多 | ||||||
N/A | 22 | Placebo | 積醖鏇繭選窪築淵鬱餘(鑰鬱窪膚簾齋鹹餘構衊) = 淵繭廠衊製鹽艱顧鏇選 壓鏇簾範製積網艱構構 (簾淵醖範觸壓鏇製簾積, 0.13) 更多 | - | 2014-10-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用